Our Blog Melanoma360

Featured image for “The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public”
06/09/2026

The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public

For anyone living with a history of skin cancer—or working to prevent it—sun protection shouldn’t be just a summer habit. That’s why today’s announcement from the…
Blog - Melanoma360
, 
Breaking News
Featured image for “Fifth Annual Evening in Memory of Valerie Guild”
06/05/2026

Fifth Annual Evening in Memory of Valerie Guild

Scientific conferences are days-long meetings filled with education, data, and updates for physicians, researchers, scientists, and advocates. One of the…
Blog - Melanoma360
, 
Philanthropy
Featured image for “Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective ”
06/05/2026

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective 

Data for darovasertib in combination with crizotinib presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes”
06/05/2026

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes

Data for anzutresgene autoleucel presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support a future…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
06/05/2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Early data for imneskibart with aldesleukin presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)”
06/05/2026

Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)

Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago show that an mRNA individualized neoantigen…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Why Are Young People Tanning Again? What a New allure Feature Reveals About Melanoma Prevention Challenges”
06/03/2026

Why Are Young People Tanning Again? What a New allure Feature Reveals About Melanoma Prevention Challenges

A recent feature in allure magazine explores a concerning trend: The resurgence of tanning culture among younger generations. The article…
Blog - Melanoma360
Featured image for “Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA”
05/29/2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies,…
Blog - Melanoma360
, 
Breaking News
Featured image for “The Importance of Self-Advocacy”
05/26/2026

The Importance of Self-Advocacy

by Mara Klecker Donna Altes was in her late 70s when she received her melanoma diagnosis, which came after a…
Blog - Melanoma360
, 
Survivor Stories
Featured image for “Webinar: Post-ASCO Melanoma Research Update”
05/21/2026

Webinar: Post-ASCO Melanoma Research Update

Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together leading cancer researchers and physicians from around…
Blog - Melanoma360
, 
Melanoma Research
06/09/2026

The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public

For anyone living with a history of skin cancer—or working to prevent it—sun protection shouldn’t be just a summer habit. That’s why today’s announcement from the…
Featured image for “The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public”
Blog - Melanoma360
 | 
Breaking News
06/05/2026

Fifth Annual Evening in Memory of Valerie Guild

Scientific conferences are days-long meetings filled with education, data, and updates for physicians, researchers, scientists, and advocates. One of the…
Featured image for “Fifth Annual Evening in Memory of Valerie Guild”
Blog - Melanoma360
 | 
Philanthropy
06/05/2026

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective 

Data for darovasertib in combination with crizotinib presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago…
Featured image for “Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective ”
Blog - Melanoma360
 | 
Melanoma Research
06/05/2026

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes

Data for anzutresgene autoleucel presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support a future…
Featured image for “Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes”
Blog - Melanoma360
 | 
Melanoma Research
06/05/2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Early data for imneskibart with aldesleukin presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support…
Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
Blog - Melanoma360
 | 
Melanoma Research
06/05/2026

Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)

Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago show that an mRNA individualized neoantigen…
Featured image for “Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)”
Blog - Melanoma360
 | 
Melanoma Research
06/03/2026

Why Are Young People Tanning Again? What a New allure Feature Reveals About Melanoma Prevention Challenges

A recent feature in allure magazine explores a concerning trend: The resurgence of tanning culture among younger generations. The article…
Featured image for “Why Are Young People Tanning Again? What a New allure Feature Reveals About Melanoma Prevention Challenges”
Blog - Melanoma360
05/29/2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies,…
Featured image for “Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA”
Blog - Melanoma360
 | 
Breaking News
05/26/2026

The Importance of Self-Advocacy

by Mara Klecker Donna Altes was in her late 70s when she received her melanoma diagnosis, which came after a…
Featured image for “The Importance of Self-Advocacy”
Blog - Melanoma360
 | 
Survivor Stories
05/21/2026

Webinar: Post-ASCO Melanoma Research Update

Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together leading cancer researchers and physicians from around…
Featured image for “Webinar: Post-ASCO Melanoma Research Update”
Blog - Melanoma360
 | 
Melanoma Research

Recent Posts

Featured image for “The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public”
Jun. 09, 2026

The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public

Featured image for “Fifth Annual Evening in Memory of Valerie Guild”
Jun. 05, 2026

Fifth Annual Evening in Memory of Valerie Guild

Featured image for “Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective ”
Jun. 05, 2026

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective 

Featured image for “Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes”
Jun. 05, 2026

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes

Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
Jun. 05, 2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Filter by Tag